CTLA-4 and PD-1 Pathways

Goldrath, 1999, Selecting and maintaining a diverse T-cell repertoire., Nature, 402, 255, 10.1038/46218

Fife, 2008, Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways., Immunol Rev, 224, 166, 10.1111/j.1600-065X.2008.00662.x

Greenwald, 2005, The B7 family revisited., Annu Rev Immunol, 23, 515, 10.1146/annurev.immunol.23.021704.115611

Krummel, 1995, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation., J Exp Med, 182, 459, 10.1084/jem.182.2.459

Dunn, 2004, The immunobiology of cancer immunosurveillance and immunoediting., Immunity, 21, 137, 10.1016/j.immuni.2004.07.017

Poschke, 2011, Camouflage and sabotage: tumor escape from the immune system., Cancer Immunol Immunother, 60, 1161, 10.1007/s00262-011-1012-8

Chambers, 2001, . CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy., Annu Rev Immunol, 19, 565, 10.1146/annurev.immunol.19.1.565

Collins, 2002, . The interaction properties of costimulatory molecules revisited., Immunity, 17, 201, 10.1016/S1074-7613(02)00362-X

Egen, 2002, CTLA-4: new insights into its biological function and use in tumor immunotherapy., Nat Immunol, 3, 611, 10.1038/ni0702-611

Parry, 2005, . CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms., Mol Cell Biol, 25, 9543, 10.1128/MCB.25.21.9543-9553.2005

Fallarino, 1998, B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28., J Exp Med, 188, 205, 10.1084/jem.188.1.205

Masteller, 2000, . Structural analysis of CTLA-4 function in vivo., J Immunol, 164, 5319, 10.4049/jimmunol.164.10.5319

Schneider, 2006, . Reversal of the TCR stop signal by CTLA-4., Science, 313, 1972, 10.1126/science.1131078

Linsley, 1996, . Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement., Immunity, 4, 535, 10.1016/S1074-7613(00)80480-X

Krummel, 1996, CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells., J Exp Med, 183, 2533, 10.1084/jem.183.6.2533

Piccirillo, 2004, Naturally-occurring CD4CD25 immunoregulatory T cells: central players in the arena of peripheral tolerance., Semin Immunol, 16, 81, 10.1016/j.smim.2003.12.003

Takahashi, 2000, . Immunologic self-tolerance maintained by CD25()CD4() regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4., J Exp Med, 192, 303, 10.1084/jem.192.2.303

Wing, 2008, . CTLA-4 control over Foxp3 regulatory T cell function., Science, 322, 271, 10.1126/science.1160062

Qureshi, 2011, . Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4., Science, 332, 600, 10.1126/science.1202947

Keir, 2008, . PD-1 and its ligands in tolerance and immunity., Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331

Bennett, 2003, . Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses., J Immunol, 170, 711, 10.4049/jimmunol.170.2.711

Wherry, 2011, T cell exhaustion., Nat Immunol, 12, 492, 10.1038/ni.2035

Chen, 2012, Molecular pathways: next-generation immunotherapyinhibiting programmed death-ligand 1 and programmed death-1., Clin Cancer Res, 18, 6580, 10.1158/1078-0432.CCR-12-1362

Latchman, 2004, . PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells., Proc Natl Acad Sci, 101, 10691, 10.1073/pnas.0307252101

Chen, 2004, Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity., Nat Rev Immunol, 4, 336, 10.1038/nri1349

Hino, 2010, . Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma., Cancer, 116, 1757, 10.1002/cncr.24899

Taube, 2014, . Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy., Clin Cancer Res, 20, 5064, 10.1158/1078-0432.CCR-13-3271

Zou, 2008, Inhibitory B7-family molecules in the tumour microenvironment., Nat Rev Immunol, 8, 467, 10.1038/nri2326

Rozali, 2012, . Programmed death ligand 2 in cancer-induced immune suppression., Clin Dev Immunol, 2012, 656340, 10.1155/2012/656340

Youngnak, 2003, . Differential binding properties of B7-H1 and B7-DC to death-1., Biochem Biophys Res Commun, 307, 672, 10.1016/S0006-291X(03)01257-9

Akbari, 2010, . PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions., Mucosal Immunol, 3, 81, 10.1038/mi.2009.112

Huber, 2010, . Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2., Blood, 116, 3311, 10.1182/blood-2010-02-271981

Butte, 2007, . Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses., Immunity, 27, 111, 10.1016/j.immuni.2007.05.016

Wang, 2008, . Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3CD4 regulatory T cells., Proc Natl Acad Sci, 105, 9331, 10.1073/pnas.0710441105

Francisco, 2009, . PD-L1 regulates the development, maintenance, and function of induced regulatory T cells., J Exp Med, 206, 3015, 10.1084/jem.20090847

Wang, 2014, . In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates., Cancer Immunol Res, 2, 846, 10.1158/2326-6066.CIR-14-0040

Ott, 2013, CTLA-4 and PD-1PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients., Clin Cancer Res, 19, 5300, 10.1158/1078-0432.CCR-13-0143

Egen, 2002, Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength., Immunity, 16, 23, 10.1016/S1074-7613(01)00259-X

Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade., Science, 271, 1734, 10.1126/science.271.5256.1734

Hirano, 2005, . Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity., Cancer Res, 65, 1089, 10.1158/0008-5472.1089.65.3

Robert, 2014, . CTLA4 blockade broadens the peripheral T-cell receptor repertoire., Clin Cancer Res, 20, 2424, 10.1158/1078-0432.CCR-13-2648

Cha, 2014, . Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients., Sci Transl Med, 6, 238, 10.1126/scitranslmed.3008211

Patel, 2015, PD-L1 expression as a predictive biomarker in cancer immunotherapy., Mol Cancer Ther, 14, 847, 10.1158/1535-7163.MCT-14-0983

Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients., Nature, 515, 563, 10.1038/nature14011

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy., Nat Rev Cancer, 12, 252, 10.1038/nrc3239

Das, 2015, . Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo., J Immunol, 194, 950, 10.4049/jimmunol.1401686

Hodi, 2010, . Improved survival with ipilimumab in patients with metastatic melanoma., N Engl J Med, 363, 711, 10.1056/NEJMoa1003466

Robert, 2011, . Ipilimumab plus dacarbazine for previously untreated metastatic melanoma., N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621

Schadendorf, 2015, . Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma., J Clin Oncol, 33, 1889, 10.1200/JCO.2014.56.2736

Farolfi, 2012, . Ipilimumab in advanced melanoma: reports of long-lasting responses., Melanoma Res, 22, 263, 10.1097/CMR.0b013e328353e65c

Robert, 2015, . KEYNOTE-006 Investigators. Pembrolizumab versus ipilimumab in advanced melanoma., N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093

Robert, 2015, . Nivolumab in previously untreated melanoma without BRAF mutation., N Engl J Med, 372, 320, 10.1056/NEJMoa1412082

Rizvi, 2015, . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial., Lancet Oncol, 16, 257, 10.1016/S1470-2045(15)70054-9

Weber, 2015, . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial., Lancet Oncol, 16, 375, 10.1016/S1470-2045(15)70076-8

Larkin, 2015, . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma., N Engl J Med, 373, 23, 10.1056/NEJMoa1504030

Brahmer, 2015, . Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer., N Engl J Med, 373, 123, 10.1056/NEJMoa1504627

Ribas, 2015, . Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial., Lancet Oncol, 16, 908, 10.1016/S1470-2045(15)00083-2

Garon, 2015, . Pembrolizumab for the treatment of non-small-cell lung cancer., N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824

Gettinger, 2015, . Overall survival and long-term safety of nivolumab (anti-programmed death-1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer., J Clin Oncol, 33, 2004, 10.1200/JCO.2014.58.3708

McDermott, 2015, . Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab., J Clin Oncol, 33, 2013, 10.1200/JCO.2014.58.1041

Topalian, 2014, . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab., J Clin Oncol, 32, 1020, 10.1200/JCO.2013.53.0105

Wolchok, 2009, . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria., Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624

Hodi, 2014, . Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475., J Clin Oncol, 32, 3006, 10.1200/jco.2014.32.15_suppl.3006

Robert, 2014, . Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial., Lancet, 384, 1109, 10.1016/S0140-6736(14)60958-2

Motzer, 2015, . Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial., J Clin Oncol, 33, 1430, 10.1200/JCO.2014.59.0703

Eisenhauer, 2009, . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)., Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Callahan, 2013, Immunomodulatory therapy for melanoma: ipilimumab and beyond., Clin Dermatol, 31, 191, 10.1016/j.clindermatol.2012.08.006

Snyder, 2014, . Genetic basis for clinical response to CTLA-4 blockade in melanoma., N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498

Powles, 2014, . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer., Nature, 515, 558, 10.1038/nature13904

Segal, 2015, . Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort., J Clin Oncol, 33, 3011, 10.1200/jco.2015.33.15_suppl.3011

Tumeh, 2014, . PD-1 blockade induces responses by inhibiting adaptive immune resistance., Nature, 515, 568, 10.1038/nature13954

Rizvi, 2015, . Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer., Science, 348, 124, 10.1126/science.aaa1348

Topalian, 2012, . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer., N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Weber, 2012, Management of immune-related adverse events and kinetics of response with ipilimumab., J Clin Oncol, 30, 2691, 10.1200/JCO.2012.41.6750

Iwama, 2014, . Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody., Sci Transl Med, 6, 230, 10.1126/scitranslmed.3008002

Rizvi, 2015, . Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)., J Clin Oncol, 33, 8032, 10.1200/jco.2015.33.15_suppl.8032

Curran, 2010, . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors., Proc Natl Acad Sci, 107, 4275, 10.1073/pnas.0915174107

Postow, 2015, . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma., N Engl J Med, 372, 2006, 10.1056/NEJMoa1414428

Selby, 2013, . Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models., J Clin Oncol, 31, 3061, 10.1200/jco.2013.31.15_suppl.3061

Wolchok, 2013, . Nivolumab plus ipilimumab in advanced melanoma., N Engl J Med, 369, 122, 10.1056/NEJMoa1302369

Hammers, 2015, . Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)., J Clin Oncol, 33, 4516, 10.1200/jco.2015.33.15_suppl.4516

Antonia, 2014, . Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results., J Clin Oncol, 32, 8023, 10.1200/jco.2014.32.15_suppl.8023

Gettinger, 2015, . First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 PD-1) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 expression., J Clin Oncol, 33, 8025, 10.1200/jco.2015.33.15_suppl.8025

Antonia, 2015, . Phase III study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032., J Clin Oncol, 33, 7503, 10.1200/jco.2015.33.15_suppl.7503

Ribas, 2014, . Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)., J Clin Oncol, 32, LBA9000, 10.1200/jco.2014.32.18_suppl.lba9000

Weber, 2013, . Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma., J Clin Oncol, 31, 4311, 10.1200/JCO.2013.51.4802